Neuromuscular adverse events following cancer treatment with anti-programmed cell death
protein 1 (PD-1) monoclonal antibodies are relatively rare, yet potentially fatal. We …

Abstract Purpose of Review In recent years, immune checkpoint inhibitors have been
increasingly used in patients with metastatic cancers with favorable oncological outcomes; …

Immune checkpoint inhibitor (ICI)-related myositis is a rare, potentially fatal condition that
warrants further studies. Its incidence, clinical features, and prognosis remain poorly …

Cancer immunotherapy has transformed the field of oncology and enabled more effective
management of previously refractory neoplasms by activation of the immune response …

Background/purpose Autoimmune diseases are diseases in which the body produces an
abnormal immune response to self-antigens and damages its own tissues. Programmed …

We report a case of lethal myocarditis and myositis after pembrolizumab treatment for
advanced upper urinary tract urothelial carcinoma. A 69-year-old man underwent …

Immune checkpoint inhibitors (ICI) induce improved clinical outcomes associated with
numerous cancers, but immune-related adverse events can occur, including neuromuscular …

Checkpoint inhibitors (CI) have revolutionized the management of many cancers but can
result in immune-related adverse events (IRAE). In this chapter, we review the clinical …

With the expanding use of immune checkpoint blockers typified by anti–programmed death-
1 (PD-1) and anti–cytotoxic T-lymphocyte-associated protein 4 monoclonal antibodies (Abs) …

Purpose of review Immune checkpoint inhibitors (ICI) are now the cornerstone of treatment
for metastatic melanoma and are increasingly used in many other advanced stage …